Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
May 13, 2014 updated by: Boehringer Ingelheim
ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.
Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31546
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Capital Federal, Argentina
- 502.373.350 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.351 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.352 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.353 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.354 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.355 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.356 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 502.373.378 Boehringer Ingelheim Investigational Site
-
Corones Suárez, Argentina
- 502.373.362 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 502.373.357 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 502.373.358 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 502.373.360 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 502.373.361 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 502.373.377 Boehringer Ingelheim Investigational Site
-
La Plata, Argentina
- 502.373.364 Boehringer Ingelheim Investigational Site
-
Mar del Plata, Argentina
- 502.373.365 Boehringer Ingelheim Investigational Site
-
Mendoza, Argentina
- 502.373.366 Boehringer Ingelheim Investigational Site
-
Mendoza, Argentina
- 502.373.376 Boehringer Ingelheim Investigational Site
-
Rosario, Argentina
- 502.373.367 Boehringer Ingelheim Investigational Site
-
Salta, Argentina
- 502.373.369 Boehringer Ingelheim Investigational Site
-
Santa Fe, Argentina
- 502.373.375 Boehringer Ingelheim Investigational Site
-
Tucumán, Argentina
- 502.373.371 Boehringer Ingelheim Investigational Site
-
Tucumán, Argentina
- 502.373.373 Boehringer Ingelheim Investigational Site
-
Zárate, Argentina
- 502.373.374 Boehringer Ingelheim Investigational Site
-
-
-
-
Australian Capital Territory
-
Woden, Australian Capital Territory, Australia
- 502.373.0534 The Canberra Hospital
-
-
New South Wales
-
Camperdown, New South Wales, Australia
- 502.373.0536 Royal Prince Alfred Hospital
-
Coffs Harbour, New South Wales, Australia
- 502.373.0544 Coffs Harbour Cardiovascular Clinic
-
Concord, New South Wales, Australia
- 502.373.0538 Concord Repatriation General Hospital
-
Gosford, New South Wales, Australia
- 502.373.0539 Central Coast Neuroscience Research
-
Gosford, New South Wales, Australia
- 502.373.0556 Gosford Hospital
-
Kogarah, New South Wales, Australia
- 502.373.0542 St. George Hospital
-
Kogarah, New South Wales, Australia
- 502.373.0552 St George Private Hospital
-
Kogarah, New South Wales, Australia
- 502.373.0559 St George Hospital - Dept of Clinical Pharmacology
-
Newcastle, New South Wales, Australia
- 502.373.0528 John Hunter Hospital
-
Randwick, New South Wales, Australia
- 502.373.0535 The Prince of Wales Hospital
-
St Leonards, New South Wales, Australia
- 502.373.0533 Royal North Shore Hospital
-
Wollongong, New South Wales, Australia
- 502.373.0549 Illawarra Regional Hospital
-
-
Queensland
-
Chermside, Queensland, Australia
- 502.373.0523 The Prince Charles Hospital
-
Herston, Queensland, Australia
- 502.373.0524 Royal Brisbane Hospital
-
Kippa-Ring, Queensland, Australia
- 502.373.0526 Peninsula Clinical Research Centre
-
Southport, Queensland, Australia
- 502.373.0540 Gold Coast Hospital
-
Woolloongabba, Queensland, Australia
- 502.373.0521 Princess Alexandra Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australia
- 502.373.0546 Flinders Medical Centre
-
Daw Park, South Australia, Australia
- 502.373.0550 Repatriation General Hospital
-
Port Lincoln, South Australia, Australia
- 502.373.0551 Port Lincoln "The Investigator" Clinic
-
-
Tasmania
-
Launceston, Tasmania, Australia
- 502.373.0529 Launceston General Hospital
-
-
Victoria
-
Box Hill, Victoria, Australia
- 502.373.0531 Box Hill Hospital
-
Epping, Victoria, Australia
- 502.373.0548 The Northern Hospital
-
Geelong, Victoria, Australia
- 502.373.0522 The Geelong Hospital
-
Parkville, Victoria, Australia
- 502.373.0520 Royal Melbourne Hospital
-
Prahran, Victoria, Australia
- 502.373.0525 The Alfred Hospital
-
Prahran, Victoria, Australia
- 502.373.0532 Baker Medical Research Centre
-
Ringwood East, Victoria, Australia
- 502.373.0557 Maroondah Hospital
-
West Heidelberg, Victoria, Australia
- 502.373.0537 Austin & Repatriation Medical Centre
-
-
Western Australia
-
Fremantle, Western Australia, Australia
- 502.373.0547 Fremantle Hospital
-
Nedlands, Western Australia, Australia
- 502.373.0530 Sir Charles Gairdner Hospital
-
Perth, Western Australia, Australia
- 502.373.0545 Royal Perth Hospital
-
-
-
-
-
Graz, Austria
- 502.373.1128 Boehringer Ingelheim Investigational Site
-
Wels, Austria
- 502.373.1125 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 502.373.1126 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 502.373.1127 Boehringer Ingelheim Investigational Site
-
Wien, Austria
- 502.373.1129 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aalst, Belgium
- 502.373.1004 Boehringer Ingelheim Investigational Site
-
Anderlecht, Belgium
- 502.373.1015 Boehringer Ingelheim Investigational Site
-
Antwerpen, Belgium
- 502.373.1005 Boehringer Ingelheim Investigational Site
-
Bornem, Belgium
- 502.373.1022 Boehringer Ingelheim Investigational Site
-
Brasschaat, Belgium
- 502.373.1021 Boehringer Ingelheim Investigational Site
-
Brugge, Belgium
- 502.373.1003 Boehringer Ingelheim Investigational Site
-
Charleroi, Belgium
- 502.373.1017 Boehringer Ingelheim Investigational Site
-
Genk, Belgium
- 502.373.1009 Boehringer Ingelheim Investigational Site
-
Godinne, Belgium
- 502.373.1018 Boehringer Ingelheim Investigational Site
-
Haine-Saint-Paul, Belgium
- 502.373.1011 Boehringer Ingelheim Investigational Site
-
Haine-Saint-Paul, Belgium
- 502.373.1019 Boehringer Ingelheim Investigational Site
-
Hasselt, Belgium
- 502.373.1007 Boehringer Ingelheim Investigational Site
-
Leuven, Belgium
- 502.373.1000 Boehringer Ingelheim Investigational Site
-
Mechelen, Belgium
- 502.373.1020 Boehringer Ingelheim Investigational Site
-
Mol, Belgium
- 502.373.1006 Boehringer Ingelheim Investigational Site
-
Roeselare, Belgium
- 502.373.1028 Boehringer Ingelheim Investigational Site
-
Seraing, Belgium
- 502.373.1014 Boehringer Ingelheim Investigational Site
-
Turnhout, Belgium
- 502.373.1002 Boehringer Ingelheim Investigational Site
-
Turnhout, Belgium
- 502.373.1010 Boehringer Ingelheim Investigational Site
-
Woluwé-Saint-Lambert, Belgium
- 502.373.1025 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Belo Horizonte, Brazil
- 502.373.405 Boehringer Ingelheim Investigational Site
-
Belo Horizonte, Brazil
- 502.373.412 Boehringer Ingelheim Investigational Site
-
Belo Horizonte, Brazil
- 502.373.426 Boehringer Ingelheim Investigational Site
-
Botucatu -, Brazil
- 502.373.418 Boehringer Ingelheim Investigational Site
-
Campinas, Brazil
- 502.373.407 Boehringer Ingelheim Investigational Site
-
Campinas, Brazil
- 502.373.419 Boehringer Ingelheim Investigational Site
-
Cerqueira César - São Paulo, Brazil
- 502.373.425 Boehringer Ingelheim Investigational Site
-
Curitiba, Brazil
- 502.373.406 Boehringer Ingelheim Investigational Site
-
Goiania, Brazil
- 502.373.411 Boehringer Ingelheim Investigational Site
-
Marília, Brazil
- 502.373.403 Boehringer Ingelheim Investigational Site
-
Pelotas, Brazil
- 502.373.400 Boehringer Ingelheim Investigational Site
-
Porto Alegre, Brazil
- 502.373.416 Boehringer Ingelheim Investigational Site
-
Porto Alegre, Brazil
- 502.373.417 Boehringer Ingelheim Investigational Site
-
Porto Alegre - Rs, Brazil
- 502.373.415 Boehringer Ingelheim Investigational Site
-
Ribeirao Preto, Brazil
- 502.373.420 Boehringer Ingelheim Investigational Site
-
Rio de Janeiro, Brazil
- 502.373.414 Boehringer Ingelheim Investigational Site
-
Rio de Janeiro - Rj, Brazil
- 502.373.413 Boehringer Ingelheim Investigational Site
-
Salvador, Brazil
- 502.373.409 Boehringer Ingelheim Investigational Site
-
Salvador, Brazil
- 502.373.410 Boehringer Ingelheim Investigational Site
-
Santa Catalina, Brazil
- 502.373.404 Boehringer Ingelheim Investigational Site
-
Sao Jose do Rio Preto, Brazil
- 502.373.421 Boehringer Ingelheim Investigational Site
-
Sao Paulo, Brazil
- 502.373.422 Boehringer Ingelheim Investigational Site
-
São Paulo, Brazil
- 502.373.402 Boehringer Ingelheim Investigational Site
-
São Paulo, Brazil
- 502.373.408 Boehringer Ingelheim Investigational Site
-
São Paulo, Brazil
- 502.373.424 Boehringer Ingelheim Investigational Site
-
Vila Clementino, São Paulo, Brazil
- 502.373.423 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Manitoba, Canada
- 502.373.0030 Portage Clinical Studies
-
Quebec, Canada
- 502.373.0028 Hop. Du St. Sacrement
-
Quebec, Canada
- 502.373.0041 Recherches Clinicar Inc.
-
Quebec, Canada
- 502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de
-
Quebec, Canada
- 502.373.0084 CHA-Hopital de l'Efant-Jesus
-
-
Alberta
-
Calgary, Alberta, Canada
- 502.373.0001 C849 Division of Cardiology, Foothills Medical Centre
-
Calgary, Alberta, Canada
- 502.373.0071 Peter Lougheed Centre
-
Edmonton, Alberta, Canada
- 502.373.0020 CHA/University Hospital
-
-
British Columbia
-
Campbell river, British Columbia, Canada
- 502.373.0073 Alder Medical Centre
-
Coquitlam, British Columbia, Canada
- 502.373.0062 Gain Medical Centre
-
Kelowna, British Columbia, Canada
- 502.373.0046 Interior Clinical Research Consultants Ltd
-
New Westminster, British Columbia, Canada
- 502.373.0038 New West Cardiac Research
-
North Vancouver, British Columbia, Canada
- 502.373.0048 Suite 100
-
Penticton, British Columbia, Canada
- 502.373.0002 Penticton Regional Hospital
-
Vancouver, British Columbia, Canada
- 502.373.0009 Vancouver Hospital
-
Victoria, British Columbia, Canada
- 502.373.0003 Discovery Clinical Services Ltd
-
-
Manitoba
-
St. Pierre, Manitoba, Canada
- 502.373.0050 St. Pierre Medical Clinic
-
Winnipeg, Manitoba, Canada
- 502.373.0077 Health Science Centre Diabetes Research Group
-
-
Newfoundland and Labrador
-
ST John's, Newfoundland and Labrador, Canada
- 502.373.0005 Dr. Jeffrey Hiscock
-
St. John's, Newfoundland and Labrador, Canada
- 502.373.0006 The General Hospital
-
-
Nova Scotia
-
Antigonish, Nova Scotia, Canada
- 502.373.0056 Antigonish Clinical Trials
-
Halifax, Nova Scotia, Canada
- 502.373.0045 Queen Elizabeth II HSC
-
-
Ontario
-
Brampton, Ontario, Canada
- 502.373.0031 Brampton Research Associates
-
Hamilton, Ontario, Canada
- 502.373.0011 St. Joseph's Hospital Cardiac Research
-
Hamilton, Ontario, Canada
- 502.373.0034 HGH McMaster Clinic
-
Hamilton, Ontario, Canada
- 502.373.0035 Hamilton Medical Research
-
Hamilton, Ontario, Canada
- 502.373.0064 Chedoke Hospital
-
Hamilton, Ontario, Canada
- 502.373.0082 3U4, McMaster University Medical Centre
-
Hamilton, Ontario, Canada
- 502.373.0085 HGH McMaster Clinic
-
London, Ontario, Canada
- 502.373.0024 London HSC - University Hospital
-
Mississauga, Ontario, Canada
- 502.373.0044 Mississauga Clinical Research Centre
-
New Westminster, Ontario, Canada
- 502.373.0043 Fraser Clinical Trial Inc
-
Newmarket, Ontario, Canada
- 502.373.0032 New Market Cardiology Research Grp
-
Niagara Falls, Ontario, Canada
- 502.373.0037 Niagara Falls Medical Centre
-
Orleans, Ontario, Canada
- 502.373.0054 Orleans Medical-Dental Centre
-
Oshawa, Ontario, Canada
- 502.373.0058 Medical Sciences Building
-
Oshawa, Ontario, Canada
- 502.373.0063 Paradigm Clinical Trials
-
Ottawa, Ontario, Canada
- 502.373.0029 Riverside Professional Building
-
Ottawa, Ontario, Canada
- 502.373.0051 Merivale Cardiovascular Consultants
-
Rexdale, Ontario, Canada
- 502.373.0040 Etobicok Cardiology
-
Sault Ste Marie, Ontario, Canada
- 502.373.0023 Group Health Centre - Clinical Trials
-
Scarborough, Ontario, Canada
- 502.373.0039 Scarborough Cardiology Research
-
Sudbury, Ontario, Canada
- 502.373.0007 Sudbury Cardiac Research
-
Thunder Bay, Ontario, Canada
- 502.373.0061 CLIKS Medical Research Corp
-
Toronto, Ontario, Canada
- 502.373.0042 Sunnybrook & Woman's College Health Science Centre
-
Toronto, Ontario, Canada
- 502.373.0083 St. Michael's Hospital
-
Willowdale, Ontario, Canada
- 502.373.0052 Dr. Bruce Lubelsky
-
Windsor, Ontario, Canada
- 502.373.0008 Windsor Health Clinic
-
-
Quebec
-
Fleurimont, Quebec, Canada
- 502.373.0081 Centre de recherche clinique, CUSE 3001
-
Gatineau, Quebec, Canada
- 502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau
-
Laval, Quebec, Canada
- 502.373.0057 Centre De Recherche Clinique
-
Levis, Quebec, Canada
- 502.373.0033 Clinique de Cardiologie de Levis
-
Longueuil, Quebec, Canada
- 502.373.0010 Recherche Invascor
-
Longueuil, Quebec, Canada
- 502.373.0013 Suite 170
-
Longueuil, Quebec, Canada
- 502.373.0014 Via Car Recherche Clinique Inc
-
Longueuil, Quebec, Canada
- 502.373.0015 C/O Peter Carmichael
-
Longueuil, Quebec, Canada
- 502.373.0016 Suite 170
-
Longueuil, Quebec, Canada
- 502.373.0017 Suite 170
-
Longueuil, Quebec, Canada
- 502.373.0086 Via Car Recherche Clinique Inc
-
Montreal, Quebec, Canada
- 502.373.0018 Montreal Heart Institute
-
Montreal, Quebec, Canada
- 502.373.0021 Medi - recherche Inc.
-
Montreal, Quebec, Canada
- 502.373.0022 CHUM - Hotel Dieu
-
Montreal, Quebec, Canada
- 502.373.0025 Hopital Maisonneuve Rosemont
-
Montreal, Quebec, Canada
- 502.373.0079 Jewish General Hospital
-
St George de Beauce, Quebec, Canada
- 502.373.0027 Ctr Hospitalier Beauce Etchemin
-
Ste-Foy, Quebec, Canada
- 502.373.0012 Hopital Laval - Institute Cardiologie de Quebec
-
Terrebonne, Quebec, Canada
- 502.373.0026 Centre hospitalier Pierre-Le Gardeur
-
Thetford Mines, Quebec, Canada
- 502.373.0072 Chra
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- 502.373.0053 Mount Royal Clinic
-
Saskatoon, Saskatchewan, Canada
- 502.373.0055 Specialists - Internal Medicine
-
Saskatoon, Saskatchewan, Canada
- 502.373.0066 SDRI - University of Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- 502.373.0067 SDRI - University of Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- 502.373.0068 SDRI - University of Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- 502.373.0070 SDRI - University of Saskatchewan
-
-
-
-
-
Beijing, China
- 502.373.0601 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0602 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0603 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0604 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0605 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0606 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0607 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0621 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0622 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0623 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 502.373.0626 Boehringer Ingelheim Investigational Site
-
Changsha, China
- 502.373.0616 Boehringer Ingelheim Investigational Site
-
Chengdu, China
- 502.373.0613 Boehringer Ingelheim Investigational Site
-
Chengdu, China
- 502.373.0625 Boehringer Ingelheim Investigational Site
-
Guangzhou, China
- 502.373.0620 Boehringer Ingelheim Investigational Site
-
Harbin, China
- 502.373.0612 Boehringer Ingelheim Investigational Site
-
HeBei Province, China
- 502.373.0634 Boehringer Ingelheim Investigational Site
-
Henan Province, China
- 502.373.0624 Boehringer Ingelheim Investigational Site
-
Hubei Province, China
- 502.373.0627 Boehringer Ingelheim Investigational Site
-
Nanjing, China
- 502.373.0614 Boehringer Ingelheim Investigational Site
-
QingDao, China
- 502.373.0629 Boehringer Ingelheim Investigational Site
-
ShanDong Province, China
- 502.373.0632 Boehringer Ingelheim Investigational Site
-
ShanDong Province, China
- 502.373.0633 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 502.373.0617 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 502.373.0618 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 502.373.0619 Boehringer Ingelheim Investigational Site
-
Shen Yang, China
- 502.373.0628 Boehringer Ingelheim Investigational Site
-
Shijiazhuang, China
- 502.373.0611 Boehringer Ingelheim Investigational Site
-
Tianjin, China
- 502.373.0615 Boehringer Ingelheim Investigational Site
-
Tianjin, China
- 502.373.0631 Boehringer Ingelheim Investigational Site
-
Weizikeng, China
- 502.373.0630 Boehringer Ingelheim Investigational Site
-
Wuhan, China
- 502.373.0608 Boehringer Ingelheim Investigational Site
-
Zhenzhou, China
- 502.373.0610 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brno, Czech Republic
- 502.373.1053 Boehringer Ingelheim Investigational Site
-
Havirov, Czech Republic
- 502.373.1060 Boehringer Ingelheim Investigational Site
-
Kladno, Czech Republic
- 502.373.1055 Boehringer Ingelheim Investigational Site
-
Mlada Boleslav, Czech Republic
- 502.373.1059 Boehringer Ingelheim Investigational Site
-
Plzen, Czech Republic
- 502.373.1061 Boehringer Ingelheim Investigational Site
-
Prague, Czech Republic
- 502.373.1057 Boehringer Ingelheim Investigational Site
-
Prague 5, Czech Republic
- 502.373.1051 Boehringer Ingelheim Investigational Site
-
Praha 2, Czech Republic
- 502.373.1062 Boehringer Ingelheim Investigational Site
-
Pribram 1, Czech Republic
- 502.373.1056 Boehringer Ingelheim Investigational Site
-
Usti nad Orlici, Czech Republic
- 502.373.1058 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aalborg, Denmark
- 502.373.1450 Boehringer Ingelheim Investigational Site
-
Aarhus C, Denmark
- 502.373.1453 Boehringer Ingelheim Investigational Site
-
Frederiksberg, Denmark
- 502.373.1455 Boehringer Ingelheim Investigational Site
-
Frederiksberg C, Denmark
- 502.373.1459 Boehringer Ingelheim Investigational Site
-
Helsingoer, Denmark
- 502.373.1460 Boehringer Ingelheim Investigational Site
-
Hilleroed, Denmark
- 502.373.1458 Boehringer Ingelheim Investigational Site
-
Holbaek, Denmark
- 502.373.1451 Boehringer Ingelheim Investigational Site
-
Hvidovre, Denmark
- 502.373.1452 Boehringer Ingelheim Investigational Site
-
Kjellerup, Denmark
- 502.373.1461 Boehringer Ingelheim Investigational Site
-
Randers, Denmark
- 502.373.1456 Boehringer Ingelheim Investigational Site
-
Slagelse, Denmark
- 502.373.1457 Boehringer Ingelheim Investigational Site
-
Svendborg, Denmark
- 502.373.1454 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Helsinki, Finland
- 502.373.1470 Boehringer Ingelheim Investigational Site
-
Helsinki, Finland
- 502.373.1473 Boehringer Ingelheim Investigational Site
-
Hämeenlinna, Finland
- 502.373.1486 Boehringer Ingelheim Investigational Site
-
Jyväskylä, Finland
- 502.373.1479 Boehringer Ingelheim Investigational Site
-
Kuopio, Finland
- 502.373.1488 Boehringer Ingelheim Investigational Site
-
Kuusankoski, Finland
- 502.373.1481 Boehringer Ingelheim Investigational Site
-
Liperi, Finland
- 502.373.1487 Boehringer Ingelheim Investigational Site
-
Oulun kaupunki, Finland
- 502.373.1475 Boehringer Ingelheim Investigational Site
-
Turku, Finland
- 502.373.1471 Boehringer Ingelheim Investigational Site
-
Vantaa, Finland
- 502.373.1485 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Albens, France
- 502.373.1093 Cabinet Médical
-
Beziers, France
- 502.373.1090 Cabinet Médical
-
Bourges, France
- 502.373.1075 Cabinet Médical
-
Broglie, France
- 502.373.1091 Cabinet Médical
-
Castelnaudary, France
- 502.373.1097 Cabinet Médical
-
Gemenos, France
- 502.373.1089 Cabinet Médical
-
Husseren Wesserlin, France
- 502.373.1099 Cabinet Médical
-
Hyeres, France
- 502.373.1094 Cabinet Médical
-
L'Aigle, France
- 502.373.1078 Cabinet Médical des Tanneurs
-
La Rochelle, France
- 502.373.1096 Cabinet Médical
-
Le Pradet, France
- 502.373.1081 Cabinet Médical
-
Murs Erigne, France
- 502.373.1083 Cabinet Médical
-
Nantes, France
- 502.373.1084 Cabinet Médical
-
Nantes, France
- 502.373.1086 Cabinet Médical
-
Niort, France
- 502.373.1080 Cabinet Médical
-
Ortez, France
- 502.373.1095 Cabinet Médical
-
Paris, France
- 502.373.1079 Cabinet Médical
-
Rennes, France
- 502.373.1088 Cabinet Médical
-
Rosiers d'Egletons, France
- 502.373.1098 Cabinet Médical
-
Saint Julien des Landes, France
- 502.373.1085 Cabinet Médical
-
Saint Martin dHyeres, France
- 502.373.1076 Cabinet Médical La Grande Ramée
-
Saint Pierre de Chandieu, France
- 502.373.1092 Cabinet Médical de St Pierre
-
Saint Romain sur Cher, France
- 502.373.1077 Cabinet Médical
-
Strasbourg, France
- 502.373.1087 Cabinet Médical
-
Tours, France
- 502.373.1082 Cabinet Médical
-
-
-
-
-
Bad Lausick, Germany
- 502.373.1164 Boehringer Ingelheim Investigational Site
-
Bad Lauterberg, Germany
- 502.373.1166 Boehringer Ingelheim Investigational Site
-
Bad Mergentheim, Germany
- 502.373.1138 Boehringer Ingelheim Investigational Site
-
Berlin, Germany
- 502.373.1156 Boehringer Ingelheim Investigational Site
-
Berlin, Germany
- 502.373.1160 Boehringer Ingelheim Investigational Site
-
Berlin, Germany
- 502.373.1161 Boehringer Ingelheim Investigational Site
-
Bielefeld, Germany
- 502.373.1144 Boehringer Ingelheim Investigational Site
-
Dessau, Germany
- 502.373.1152 Boehringer Ingelheim Investigational Site
-
Dortmund, Germany
- 502.373.1139 Boehringer Ingelheim Investigational Site
-
Dortmund, Germany
- 502.373.1159 Boehringer Ingelheim Investigational Site
-
Dresden, Germany
- 502.373.1136 Boehringer Ingelheim Investigational Site
-
Eberswalde, Germany
- 502.373.1145 Boehringer Ingelheim Investigational Site
-
Erlangen, Germany
- 502.373.1155 Boehringer Ingelheim Investigational Site
-
Essen, Germany
- 502.373.1157 Boehringer Ingelheim Investigational Site
-
Haag, Germany
- 502.373.1153 Boehringer Ingelheim Investigational Site
-
Hamburg, Germany
- 502.373.1148 Boehringer Ingelheim Investigational Site
-
Heidelberg, Germany
- 502.373.1132 Boehringer Ingelheim Investigational Site
-
Homburg/Saar, Germany
- 502.373.1131 Boehringer Ingelheim Investigational Site
-
Karlsburg, Germany
- 502.373.1147 Boehringer Ingelheim Investigational Site
-
Kelkheim, Germany
- 502.373.1154 Boehringer Ingelheim Investigational Site
-
Köln, Germany
- 502.373.1137 Boehringer Ingelheim Investigational Site
-
Künzing, Germany
- 502.373.1142 Boehringer Ingelheim Investigational Site
-
Lübeck, Germany
- 502.373.1165 Boehringer Ingelheim Investigational Site
-
Mainz, Germany
- 502.373.1134 Boehringer Ingelheim Investigational Site
-
Melsungen, Germany
- 502.373.1133 Boehringer Ingelheim Investigational Site
-
München, Germany
- 502.373.1146 Boehringer Ingelheim Investigational Site
-
Offenbach am Main, Germany
- 502.373.1149 Boehringer Ingelheim Investigational Site
-
Riesa, Germany
- 502.373.1162 Boehringer Ingelheim Investigational Site
-
Rostock, Germany
- 502.373.1140 Boehringer Ingelheim Investigational Site
-
Sindelfingen, Germany
- 502.373.1150 Boehringer Ingelheim Investigational Site
-
Starnberg, Germany
- 502.373.1163 Boehringer Ingelheim Investigational Site
-
Stuttgart, Germany
- 502.373.1158 Boehringer Ingelheim Investigational Site
-
Timmendorfer Strand, Germany
- 502.373.1167 Boehringer Ingelheim Investigational Site
-
Wiesbaden, Germany
- 502.373.1135 Boehringer Ingelheim Investigational Site
-
Witten, Germany
- 502.373.1141 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Athens, Greece
- 502.373.1200 Boehringer Ingelheim Investigational Site
-
Athens, Greece
- 502.373.1203 Boehringer Ingelheim Investigational Site
-
Athens, Greece
- 502.373.1206 Boehringer Ingelheim Investigational Site
-
Athens, Greece
- 502.373.1207 Boehringer Ingelheim Investigational Site
-
Athens, Greece
- 502.373.1208 Boehringer Ingelheim Investigational Site
-
Athens, Greece
- 502.373.1214 Boehringer Ingelheim Investigational Site
-
Elefsina, Greece
- 502.373.1209 Boehringer Ingelheim Investigational Site
-
Goudi/ Athens, Greece
- 502.373.1211 Boehringer Ingelheim Investigational Site
-
Ioannina, Greece
- 502.373.1201 Boehringer Ingelheim Investigational Site
-
Kavala,greece, Greece
- 502.373.1210 Boehringer Ingelheim Investigational Site
-
Korinthos, Greece
- 502.373.1224 Boehringer Ingelheim Investigational Site
-
Melissia, Athens, Greece
- 502.373.1202 Boehringer Ingelheim Investigational Site
-
Thessaloniki, Greece
- 502.373.1205 Boehringer Ingelheim Investigational Site
-
Thessaloniki, Greece
- 502.373.1213 Boehringer Ingelheim Investigational Site
-
Veria, Greece
- 502.373.1204 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- 502.373.0676 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 502.373.0677 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 502.373.0680 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 502.373.0681 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 502.373.0685 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Budapest, Hungary
- 502.373.1227 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1230 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1231 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1232 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1233 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1235 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1237 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1239 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1242 Boehringer Ingelheim Investigational Site
-
Budapest, Hungary
- 502.373.1244 Boehringer Ingelheim Investigational Site
-
Debrecen, Hungary
- 502.373.1236 Boehringer Ingelheim Investigational Site
-
Debrecen, Hungary
- 502.373.1240 Boehringer Ingelheim Investigational Site
-
Kecskemet, Hungary
- 502.373.1228 Boehringer Ingelheim Investigational Site
-
Nyiregyhaza, Hungary
- 502.373.1241 Boehringer Ingelheim Investigational Site
-
Pecs, Hungary
- 502.373.1226 Boehringer Ingelheim Investigational Site
-
Siofok, Hungary
- 502.373.1229 Boehringer Ingelheim Investigational Site
-
Szeged, Hungary
- 502.373.1238 Boehringer Ingelheim Investigational Site
-
Szekesfehervar, Hungary
- 502.373.1225 Boehringer Ingelheim Investigational Site
-
Tatabanya, Hungary
- 502.373.1234 Boehringer Ingelheim Investigational Site
-
Veszprem, Hungary
- 502.373.1243 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Dublin 24, Ireland
- 502.373.1717 Adelaide & Meath Hospitals
-
Dublin 8, Ireland
- 502.373.1714 Dept. of Clinical Pharmacology
-
Dublin 9, Ireland
- 502.373.1719 Pulmonary Function Laboratory
-
Mallow, Ireland
- 502.373.1720 Mallow General Hospital
-
-
-
-
-
Ascoli Piceno, Italy
- 502.373.1257 Ospedale "Mazzoni"
-
Bentivoglio (BO), Italy
- 502.373.1259 Ospedale di Bentivoglio
-
Bologna, Italy
- 502.373.1255 Ospedale "S. Orsola Malpighi"
-
Bologna, Italy
- 502.373.1278 Ospedale Bellaria
-
Brescia, Italy
- 502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia
-
Casarano (LE), Italy
- 502.373.1261 Ospedale Civile di Casarano
-
Caserta, Italy
- 502.373.1252 Azienda Ospedaliera di Caserta
-
Città della Pieve (PG), Italy
- 502.373.1254 Ospedale di Città della Pieve
-
Ferrara, Italy
- 502.373.1262 Arcispedale "S. Anna"
-
Monfalcone (go), Italy
- 502.373.1250 Ospedale Civile "S. Polo"
-
Napoli, Italy
- 502.373.1266 Azienda Universitaria Policlinico "Federico II"
-
Napoli, Italy
- 502.373.1267 Azienda Universitaria Policlinico II
-
Napoli, Italy
- 502.373.1269 Università Federico II
-
Napoli, Italy
- 502.373.1279 Asl Na 1
-
Palermo, Italy
- 502.373.1264 Presidio Ospedaliero "Villa Sofia"
-
Pavia, Italy
- 502.373.1265 IRCCS - Policlinico S. Matteo
-
Perugia, Italy
- 502.373.1251 Policlinico Monteluce
-
Perugia, Italy
- 502.373.1258 Ospedale "R. Silvestrini"
-
Perugia, Italy
- 502.373.1274 Ospedale "R. Silvestrini"
-
Pozzilli (IS), Italy
- 502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS
-
Roma, Italy
- 502.373.1263 Policlinico Umberto I
-
Roma, Italy
- 502.373.1268 Ospedale "S. Spirito"
-
Roma, Italy
- 502.373.1270 Policlinico di Tor Vergata
-
Roma, Italy
- 502.373.1273 A.O. "S. Camillo de Lellis"
-
S. Pietro Vernotico (BR), Italy
- 502.373.1260 Ospedale "N. Melli"
-
Sassari, Italy
- 502.373.1256 Ospedale Civile SS. Annunziata - USL 1
-
Torino, Italy
- 502.373.1277 A.S.O. "S. Giovanni Battista"
-
Varese, Italy
- 502.373.1272 Ospedale di Circolo di Varese
-
Venezia, Italy
- 502.373.1271 Ospedale Civile
-
Viterbo, Italy
- 502.373.1276 Ospedale Belcolle
-
-
-
-
-
Incheon, Korea, Republic of
- 502.373.0763 Boehringer Ingelheim Investigational Site
-
Kwang-ju, Korea, Republic of
- 502.373.0764 Boehringer Ingelheim Investigational Site
-
Pusan, Korea, Republic of
- 502.373.0755 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 502.373.0750 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 502.373.0753 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 502.373.0756 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 502.373.0757 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 502.373.0760 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 502.373.0761 Boehringer Ingelheim Investigational Site
-
Taegu, Korea, Republic of
- 502.373.0754 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Johor Baharu, Malaysia
- 502.373.0736 Boehringer Ingelheim Investigational Site
-
Kelantan, Malaysia
- 502.373.0739 Boehringer Ingelheim Investigational Site
-
Kelantan Darul Naim, Malaysia
- 502.373.2707 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malaysia
- 502.373.0732 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malaysia
- 502.373.0734 Boehringer Ingelheim Investigational Site
-
Penang, Malaysia
- 502.373.0733 Boehringer Ingelheim Investigational Site
-
Putrajaya, Malaysia
- 502.373.0731 Boehringer Ingelheim Investigational Site
-
Selangor, Malaysia
- 502.373.60001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Guadalajara, Mexico
- 502.373.0450 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 502.373.0451 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 502.373.0452 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 502.373.0459 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 502.373.0460 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 502.373.0461 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 502.373.0470 Boehringer Ingelheim Investigational Site
-
Mexico, Mexico
- 502.373.0457 Boehringer Ingelheim Investigational Site
-
Mexico, Mexico
- 502.373.0458 Boehringer Ingelheim Investigational Site
-
Monterrey, Mexico
- 502.373.0454 Boehringer Ingelheim Investigational Site
-
Zapopan, Mexico
- 502.373.0453 Boehringer Ingelheim Investigational Site
-
Zapopan, Mexico
- 502.373.0456 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amsterdam, Netherlands
- 502.373.1309 Boehringer Ingelheim Investigational Site
-
Beverwijk, Netherlands
- 502.373.1305 Boehringer Ingelheim Investigational Site
-
Den Bosch, Netherlands
- 502.373.1313 Boehringer Ingelheim Investigational Site
-
Den Haag, Netherlands
- 502.373.1312 Boehringer Ingelheim Investigational Site
-
Doetinchem, Netherlands
- 502.373.1302 Boehringer Ingelheim Investigational Site
-
Drachten, Netherlands
- 502.373.1304 Boehringer Ingelheim Investigational Site
-
Eindhoven, Netherlands
- 502.373.1301 Boehringer Ingelheim Investigational Site
-
Ermelo, Netherlands
- 502.373.1318 Boehringer Ingelheim Investigational Site
-
Ewijk, Netherlands
- 502.373.1320 Boehringer Ingelheim Investigational Site
-
Hengelo, Netherlands
- 502.373.1310 Boehringer Ingelheim Investigational Site
-
Hoorn, Netherlands
- 502.373.1303 Boehringer Ingelheim Investigational Site
-
Huizen, Netherlands
- 502.373.1322 Boehringer Ingelheim Investigational Site
-
Lichtenvoorde, Netherlands
- 502.373.1300 Boehringer Ingelheim Investigational Site
-
Losser, Netherlands
- 502.373.1323 Boehringer Ingelheim Investigational Site
-
Nieuwegein, Netherlands
- 502.373.1307 Boehringer Ingelheim Investigational Site
-
Rijswijk, Netherlands
- 502.373.1317 Boehringer Ingelheim Investigational Site
-
Roelofarendsveen, Netherlands
- 502.373.1319 Boehringer Ingelheim Investigational Site
-
Rotterdam, Netherlands
- 502.373.1308 Boehringer Ingelheim Investigational Site
-
Spijkenisse, Netherlands
- 502.373.1321 Boehringer Ingelheim Investigational Site
-
Stadskanaal, Netherlands
- 502.373.1311 Boehringer Ingelheim Investigational Site
-
Tilburg, Netherlands
- 502.373.1314 Boehringer Ingelheim Investigational Site
-
Utrecht, Netherlands
- 502.373.1316 Boehringer Ingelheim Investigational Site
-
Velp, Netherlands
- 502.373.1315 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Auckland, New Zealand
- 502.373.0500 Boehringer Ingelheim Investigational Site
-
Auckland 3, New Zealand
- 502.373.0502 Boehringer Ingelheim Investigational Site
-
Christchurch, New Zealand
- 502.373.0507 Boehringer Ingelheim Investigational Site
-
Hamiton, New Zealand
- 502.373.0504 Boehringer Ingelheim Investigational Site
-
Hasting, New Zealand
- 502.373.0506 Boehringer Ingelheim Investigational Site
-
Otahuhu Auckland, New Zealand
- 502.373.0501 Middlemore Hospital
-
Takapuna Auckland, New Zealand
- 502.373.0503 Boehringer Ingelheim Investigational Site
-
Tauranga, New Zealand
- 502.373.0505 Tauranga Study Centre
-
-
-
-
-
Fevik, Norway
- 502.373.20003 Boehringer Ingelheim Investigational Site
-
Nesttun, Norway
- 502.373.20004 Fana Hjertesenter
-
Stavanger, Norway
- 502.373.20001 Stavanger Universitetssykehus
-
Tvedestrand, Norway
- 502.373.20002 Tvedestrand Legesenter
-
Tønsberg, Norway
- 502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg
-
-
-
-
-
Cavite, Philippines
- 502.373.0702 De La Salle University Medical Center
-
Manila, Philippines
- 502.373.0700 Philippine General Hospital
-
Manila, Philippines
- 502.373.0701 Manila Doctors Hospital, Room 3 Annex
-
Pasig City, Philippines
- 502.373.0705 The Medical City
-
Quezon City, Philippines
- 502.373.0703 Philippine Heart Center
-
Quezon City, Philippines
- 502.373.0704 National Kidney & Transplant Institute, Room 821
-
-
-
-
-
Bydgoszcz, Poland
- 502.373.1354 Boehringer Ingelheim Investigational Site
-
Czestochowa, Poland
- 502.373.1366 Boehringer Ingelheim Investigational Site
-
Gdynia, Poland
- 502.373.1368 Boehringer Ingelheim Investigational Site
-
Gdynia Redlowo, Poland
- 502.373.1365 Boehringer Ingelheim Investigational Site
-
Grojec, Poland
- 502.373.1359 Boehringer Ingelheim Investigational Site
-
Grudziadz, Poland
- 502.373.1369 Boehringer Ingelheim Investigational Site
-
Inowroclaw, Poland
- 502.373.1375 Boehringer Ingelheim Investigational Site
-
Jaroslawiec, Poland
- 502.373.1360 Boehringer Ingelheim Investigational Site
-
Katowice, Poland
- 502.373.1372 Boehringer Ingelheim Investigational Site
-
Katowice, Poland
- 502.373.1376 Boehringer Ingelheim Investigational Site
-
Kielce, Poland
- 502.373.1361 Boehringer Ingelheim Investigational Site
-
Lodz, Poland
- 502.373.1358 Boehringer Ingelheim Investigational Site
-
Lubartow, Poland
- 502.373.1364 Boehringer Ingelheim Investigational Site
-
Lubin, Poland
- 502.373.1374 Boehringer Ingelheim Investigational Site
-
Nowy Sacz, Poland
- 502.373.1367 Boehringer Ingelheim Investigational Site
-
Piotrkow Trybunalski, Poland
- 502.373.1356 Boehringer Ingelheim Investigational Site
-
Poznan, Poland
- 502.373.1370 Boehringer Ingelheim Investigational Site
-
Ruda Slaska, Poland
- 502.373.1357 Boehringer Ingelheim Investigational Site
-
Skierniewice, Poland
- 502.373.1352 Boehringer Ingelheim Investigational Site
-
Tarnow, Poland
- 502.373.1362 Boehringer Ingelheim Investigational Site
-
Tomaszow Mazowiecki, Poland
- 502.373.1355 Boehringer Ingelheim Investigational Site
-
Torun, Poland
- 502.373.1353 Boehringer Ingelheim Investigational Site
-
Warsaw, Poland
- 502.373.1351 Boehringer Ingelheim Investigational Site
-
Warsaw, Poland
- 502.373.1363 Boehringer Ingelheim Investigational Site
-
Wegrow, Poland
- 502.373.1373 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Almada, Portugal
- 502.373.1402 Hospital Garcia de Orta
-
Amadora, Portugal
- 502.373.1400 Hospital Fernando Fonseca
-
Carnaxide, Portugal, 2799-523
- 502.373.1411 Hospital de Santa Cruz
-
Coimbra, Portugal
- 502.373.1408 Hospitais da Universidade de Coimbra
-
Faro, Portugal
- 502.373.1406 Hospital Distrital de Faro Geral
-
Lisboa, Portugal
- 502.373.1403 Hospital de Santa Marta
-
Lisboa, Portugal
- 502.373.1409 Hospital de Santa Maria
-
Matosinhos, Portugal
- 502.373.1401 Unidade Local de Saúde de Matosinhos
-
Porto, Portugal
- 502.373.1410 Hospital de Santo António
-
Vila Nova de Gaia, Portugal
- 502.373.1407 Centro Hospitalar vila Nova de Gaia
-
-
-
-
-
Caguas, Puerto Rico
- 502.373.0215 Boehringer Ingelheim Investigational Site
-
Las Lomas, Puerto Rico
- 502.373.0267 Boehringer Ingelheim Investigational Site
-
Manati, Puerto Rico
- 502.373.0190 Boehringer Ingelheim Investigational Site
-
Orocovis, Puerto Rico
- 502.373.0198 Boehringer Ingelheim Investigational Site
-
Rio Piedras, Puerto Rico
- 502.373.0262 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Moscow, Russian Federation
- 502.373.1425 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 502.373.1426 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 502.373.1427 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 502.373.1428 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 502.373.1429 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 502.373.1430 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 502.373.1433 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Russian Federation
- 502.373.1431 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Russian Federation
- 502.373.1432 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kuala Lumpur, Singapore
- 502.373.2706 Boehringer Ingelheim Investigational Site
-
Singapore, Singapore
- 502.373.0725 Boehringer Ingelheim Investigational Site
-
Singapore, Singapore
- 502.373.0726 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bratislava, Slovakia
- 502.373.1535 Boehringer Ingelheim Investigational Site
-
Kosice, Slovakia
- 502.373.1529 Boehringer Ingelheim Investigational Site
-
Kosice, Slovakia
- 502.373.1540 Boehringer Ingelheim Investigational Site
-
Nitra, Slovakia
- 502.373.1538 Boehringer Ingelheim Investigational Site
-
Rimavska Sobota, Slovakia
- 502.373.1545 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bellville, South Africa
- 502.373.1553 Boehringer Ingelheim Investigational Site
-
Bloemfontein, South Africa
- 502.373.1552 Boehringer Ingelheim Investigational Site
-
Cape Town, South Africa
- 502.373.1550 Boehringer Ingelheim Investigational Site
-
Cape Town, South Africa
- 502.373.1561 Boehringer Ingelheim Investigational Site
-
Congella, South Africa
- 502.373.1554 Boehringer Ingelheim Investigational Site
-
Durban, South Africa
- 502.373.1551 Boehringer Ingelheim Investigational Site
-
Fiachrdtpark, Bloemfontein, South Africa
- 502.373.1560 Boehringer Ingelheim Investigational Site
-
George East, South Africa
- 502.373.1563 Boehringer Ingelheim Investigational Site
-
Park Town West, South Africa
- 502.373.1555 Boehringer Ingelheim Investigational Site
-
Port Elizabeth, South Africa
- 502.373.1559 Boehringer Ingelheim Investigational Site
-
Port Elizabeth, South Africa
- 502.373.1562 Boehringer Ingelheim Investigational Site
-
Soweto, South Africa
- 502.373.1558 Boehringer Ingelheim Investigational Site
-
Sunninghill, South Africa
- 502.373.1557 Boehringer Ingelheim Investigational Site
-
Sunninghill, South Africa
- 502.373.1564 Boehringer Ingelheim Investigational Site
-
Vanderbijlpark, South Africa
- 502.373.1556 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alcorcón (Madrid), Spain
- 502.373.1582 Boehringer Ingelheim Investigational Site
-
Alicante, Spain
- 502.373.1601 Boehringer Ingelheim Investigational Site
-
Barcelona, Spain
- 502.373.1586 Boehringer Ingelheim Investigational Site
-
Barcelona, Spain
- 502.373.1590 Boehringer Ingelheim Investigational Site
-
Barcelona, Spain
- 502.373.1597 Boehringer Ingelheim Investigational Site
-
Barcelona, Spain
- 502.373.1599 Boehringer Ingelheim Investigational Site
-
Burjasot (Valencia), Spain
- 502.373.1595 Boehringer Ingelheim Investigational Site
-
Granada, Spain
- 502.373.1584 Boehringer Ingelheim Investigational Site
-
Granada, Spain
- 502.373.1585 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 502.373.1576 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 502.373.1578 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 502.373.1580 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 502.373.1589 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 502.373.1592 Boehringer Ingelheim Investigational Site
-
Murcia, Spain
- 502.373.1594 Boehringer Ingelheim Investigational Site
-
Málaga, Spain
- 502.373.1577 Boehringer Ingelheim Investigational Site
-
Málaga, Spain
- 502.373.1596 Boehringer Ingelheim Investigational Site
-
Santiago de Compostela, Spain
- 502.373.1579 Boehringer Ingelheim Investigational Site
-
Santiago de Compostela, Spain
- 502.373.1593 Boehringer Ingelheim Investigational Site
-
Santiago de Compostela, Spain
- 502.373.1598 Boehringer Ingelheim Investigational Site
-
Sevilla, Spain
- 502.373.1583 Boehringer Ingelheim Investigational Site
-
Valencia, Spain
- 502.373.1575 Boehringer Ingelheim Investigational Site
-
Valencia, Spain
- 502.373.1591 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Göteborg, Sweden
- 502.373.1504 Capio Lundby sjukhus
-
Göteborg, Sweden
- 502.373.1509 Hjärtsektionen / Med.kliniken
-
Göteborg, Sweden
- 502.373.1514 Hjärt/Kärlforskn.enheten
-
Helsingborg, Sweden
- 502.373.1501 Hjaertmottagningen
-
Järfälla, Sweden
- 502.373.1505 Jakobsbergs sjukhus
-
Malmoe, Sweden
- 502.373.1502 Borgmästargaardens Läkarmottagning
-
Malmö, Sweden
- 502.373.1506 Hjärtmottagningen
-
Malmö, Sweden
- 502.373.1507 Kardiologiska kliniken
-
Malmö, Sweden
- 502.373.1508 Kolgahuset Läkargrupp
-
Sjuntorp, Sweden
- 502.373.1511 Sjuntorps Vaardcentral
-
Trollhättan, Sweden
- 502.373.1503 Källtorps Vaardcentral
-
Vännäs, Sweden
- 502.373.1512 Vännäs Vaardcentral
-
-
-
-
-
Basel, Switzerland
- 502.373.1625 Boehringer Ingelheim Investigational Site
-
Bellinzona, Switzerland
- 502.373.1632 Boehringer Ingelheim Investigational Site
-
Bern, Switzerland
- 502.373.1634 Boehringer Ingelheim Investigational Site
-
Biel/Bienne, Switzerland
- 502.373.1627 Boehringer Ingelheim Investigational Site
-
Chur, Switzerland
- 502.373.1631 Boehringer Ingelheim Investigational Site
-
Kreuzlingen, Switzerland
- 502.373.1633 Boehringer Ingelheim Investigational Site
-
Lausanne, Switzerland
- 502.373.1639 Boehringer Ingelheim Investigational Site
-
Lugano, Switzerland
- 502.373.1629 Boehringer Ingelheim Investigational Site
-
St. Gallen, Switzerland
- 502.373.1628 Boehringer Ingelheim Investigational Site
-
Zürich, Switzerland
- 502.373.1637 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Changhua, Taiwan
- 502.373.0780 Boehringer Ingelheim Investigational Site
-
Chia-Yi, Taiwan
- 502.373.0779 Boehringer Ingelheim Investigational Site
-
Hualien, Taiwan
- 502.373.0783 Boehringer Ingelheim Investigational Site
-
Kaohsiung, Taiwan
- 502.373.0776 Boehringer Ingelheim Investigational Site
-
Kaohsiung, Taiwan
- 502.373.0778 Boehringer Ingelheim Investigational Site
-
Tainan, Taiwan
- 502.373.0775 Boehringer Ingelheim Investigational Site
-
Tainan, Taiwan
- 502.373.0777 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwan
- 502.373.0781 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwan
- 502.373.0782 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bangkok, Thailand
- 502.373.0801 Boehringer Ingelheim Investigational Site
-
Bangkok, Thailand
- 502.373.0802 Boehringer Ingelheim Investigational Site
-
Bangkok, Thailand
- 502.373.0804 Boehringer Ingelheim Investigational Site
-
Bangkok, Thailand
- 502.373.0805 Boehringer Ingelheim Investigational Site
-
Bangkok, Thailand
- 502.373.0806 Boehringer Ingelheim Investigational Site
-
Bangkok, Thailand
- 502.373.0808 Boehringer Ingelheim Investigational Site
-
Khon Kaen, Thailand
- 502.373.0803 Boehringer Ingelheim Investigational Site
-
Nonthaburi, Thailand
- 502.373.0807 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Adana, Turkey
- 502.373.1651 Cukurova Universitesi Tip Fakultesi
-
Adana, Turkey
- 502.373.1652 Cukurova Universitesi Tip Fakultesi
-
Ankara, Turkey
- 502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü
-
Ankara, Turkey
- 502.373.1656 Baskent Universitesi Tip Fakultesi
-
Ankara, Turkey
- 502.373.1659 Ankara Universitesi Tip Fakultesi
-
Istanbul, Turkey
- 502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi
-
Istanbul, Turkey
- 502.373.1655 Cerrahpasa Universitesi Tip Fakultesi
-
Istanbul, Turkey
- 502.373.1657 Haseki Hastanesi
-
Izmir, Turkey
- 502.373.1658 Ege Universitesi Tip Fakultesi
-
Kayseri, Turkey
- 502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali
-
-
-
-
-
Dnyepropetrovsk, Ukraine
- 502.373.1730 Boehringer Ingelheim Investigational Site
-
Dnyepropetrovsk, Ukraine
- 502.373.1731 Boehringer Ingelheim Investigational Site
-
Kharkov, Ukraine
- 502.373.1728 Boehringer Ingelheim Investigational Site
-
Kharkov, Ukraine
- 502.373.1732 Boehringer Ingelheim Investigational Site
-
Kharkov, Ukraine
- 502.373.1733 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 502.373.1725 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 502.373.1726 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 502.373.1727 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 502.373.1729 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 502.373.1734 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Abu Dhabi, United Arab Emirates
- 502.373.1680 Boehringer Ingelheim Investigational Site
-
Dubai, United Arab Emirates
- 502.373.1675 Boehringer Ingelheim Investigational Site
-
Dubai, United Arab Emirates
- 502.373.1679 Boehringer Ingelheim Investigational Site
-
Sharjah, United Arab Emirates
- 502.373.1677 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aberdeen, United Kingdom
- 502.373.1698 Boehringer Ingelheim Investigational Site
-
Bathampton, United Kingdom
- 502.373.1706 Boehringer Ingelheim Investigational Site
-
Belfast, United Kingdom
- 502.373.1690 Boehringer Ingelheim Investigational Site
-
Birmingham, United Kingdom
- 502.373.1694 Boehringer Ingelheim Investigational Site
-
Brighton, United Kingdom
- 502.373.1707 Boehringer Ingelheim Investigational Site
-
Cardiff, United Kingdom
- 502.373.1703 Boehringer Ingelheim Investigational Site
-
Chichester, United Kingdom
- 502.373.1709 Boehringer Ingelheim Investigational Site
-
Derby, United Kingdom
- 502.373.1701 Boehringer Ingelheim Investigational Site
-
Gateshead, United Kingdom
- 502.373.1705 Boehringer Ingelheim Investigational Site
-
Glasgow, United Kingdom
- 502.373.1710 Boehringer Ingelheim Investigational Site
-
Kirkcaldy, Fife, United Kingdom
- 502.373.1700 Boehringer Ingelheim Investigational Site
-
Leeds, United Kingdom
- 502.373.1691 Boehringer Ingelheim Investigational Site
-
Leicester, United Kingdom
- 502.373.1699 Boehringer Ingelheim Investigational Site
-
Lincoln, United Kingdom
- 502.373.1702 Boehringer Ingelheim Investigational Site
-
Liverpool, United Kingdom
- 502.373.1697 Boehringer Ingelheim Investigational Site
-
London, United Kingdom
- 502.373.1695 Boehringer Ingelheim Investigational Site
-
Manchester, United Kingdom
- 502.373.1693 Boehringer Ingelheim Investigational Site
-
Portadown, County Atrim, United Kingdom
- 502.373.1708 Boehringer Ingelheim Investigational Site
-
Rugby, United Kingdom
- 502.373.1692 Boehringer Ingelheim Investigational Site
-
Sheffield, United Kingdom
- 502.373.1696 Boehringer Ingelheim Investigational Site
-
Stirling, United Kingdom
- 502.373.1704 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Athens, Alabama, United States
- 502.373.0256 Boehringer Ingelheim Investigational Site
-
Birmingham, Alabama, United States
- 502.373.0251 Boehringer Ingelheim Investigational Site
-
-
Arizona
-
Phoenix, Arizona, United States
- 502.373.0182 Boehringer Ingelheim Investigational Site
-
Phoenix, Arizona, United States
- 502.373.0188 Boehringer Ingelheim Investigational Site
-
Tucson, Arizona, United States
- 502.373.0189 Boehringer Ingelheim Investigational Site
-
Tuscon, Arizona, United States
- 502.373.0177 Boehringer Ingelheim Investigational Site
-
-
Arkansas
-
Bentonville, Arkansas, United States
- 502.373.0209 Boehringer Ingelheim Investigational Site
-
-
California
-
Concord, California, United States
- 502.373.0173 Boehringer Ingelheim Investigational Site
-
Harbor City, California, United States
- 502.373.0266 Boehringer Ingelheim Investigational Site
-
Loma Linda, California, United States
- 502.373.0283 Boehringer Ingelheim Investigational Site
-
Los Angeles, California, United States
- 502.373.0180 Boehringer Ingelheim Investigational Site
-
Sacramento, California, United States
- 502.373.0175 Boehringer Ingelheim Investigational Site
-
San Diego, California, United States
- 502.373.0165 Boehringer Ingelheim Investigational Site
-
San Leandro, California, United States
- 502.373.0228 Boehringer Ingelheim Investigational Site
-
Sylmar, California, United States
- 502.373.0205 Boehringer Ingelheim Investigational Site
-
West Hills, California, United States
- 502.373.0277 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, United States
- 502.373.0226 Boehringer Ingelheim Investigational Site
-
Farmington, Connecticut, United States
- 502.373.0174 Boehringer Ingelheim Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States
- 502.373.0258 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Gainesville, Florida, United States
- 502.373.0179 Boehringer Ingelheim Investigational Site
-
Palm Harbor, Florida, United States
- 502.373.0183 Boehringer Ingelheim Investigational Site
-
Panama City, Florida, United States
- 502.373.0240 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, United States
- 502.373.0171 Boehringer Ingelheim Investigational Site
-
Vero Beach, Florida, United States
- 502.373.0282 Boehringer Ingelheim Investigational Site
-
Weston, Florida, United States
- 502.373.0214 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Augusta, Georgia, United States
- 502.373.0161 Boehringer Ingelheim Investigational Site
-
Augusta, Georgia, United States
- 502.373.0193 Boehringer Ingelheim Investigational Site
-
Augusta, Georgia, United States
- 502.373.0201 Boehringer Ingelheim Investigational Site
-
Conyers, Georgia, United States
- 502.373.0223 Boehringer Ingelheim Investigational Site
-
Sandersville, Georgia, United States
- 502.373.0268 Boehringer Ingelheim Investigational Site
-
Savannah, Georgia, United States
- 502.373.0245 Boehringer Ingelheim Investigational Site
-
Tucker, Georgia, United States
- 502.373.0199 Boehringer Ingelheim Investigational Site
-
Valdosta, Georgia, United States
- 502.373.0162 Boehringer Ingelheim Investigational Site
-
-
Idaho
-
Pocatello, Idaho, United States
- 502.373.0203 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Burbank, Illinois, United States
- 502.373.0244 Boehringer Ingelheim Investigational Site
-
Chicago, Illinois, United States
- 502.373.0272 Boehringer Ingelheim Investigational Site
-
Olympia Fields, Illinois, United States
- 502.373.0217 Boehringer Ingelheim Investigational Site
-
-
Iowa
-
Des Moines, Iowa, United States
- 502.373.0270 Boehringer Ingelheim Investigational Site
-
-
Louisiana
-
Monroe, Louisiana, United States
- 502.373.0167 Boehringer Ingelheim Investigational Site
-
Shreveport, Louisiana, United States
- 502.373.0158 Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States
- 502.373.0247 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States
- 502.373.0284 Boehringer Ingelheim Investigational Site
-
Springfield, Massachusetts, United States
- 502.373.0229 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Wyandotte, Michigan, United States
- 502.373.0237 Boehringer Ingelheim Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- 502.373.0208 Boehringer Ingelheim Investigational Site
-
Minneapolis, Minnesota, United States
- 502.373.0232 Boehringer Ingelheim Investigational Site
-
St. Paul, Minnesota, United States
- 502.373.0231 Boehringer Ingelheim Investigational Site
-
-
Mississippi
-
Biloxi, Mississippi, United States
- 502.373.0181 Boehringer Ingelheim Investigational Site
-
Cleveland, Mississippi, United States
- 502.373.0185 Boehringer Ingelheim Investigational Site
-
Jackson, Mississippi, United States
- 502.373.0254 Boehringer Ingelheim Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States
- 502.373.0195 Boehringer Ingelheim Investigational Site
-
St. Louis, Missouri, United States
- 502.373.0207 Boehringer Ingelheim Investigational Site
-
St. Louis, Missouri, United States
- 502.373.0239 Boehringer Ingelheim Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States
- 502.373.0279 Boehringer Ingelheim Investigational Site
-
-
Nevada
-
North Las Vegas, Nevada, United States
- 502.373.0169 Boehringer Ingelheim Investigational Site
-
-
New Jersey
-
Camden, New Jersey, United States
- 502.373.0157 Boehringer Ingelheim Investigational Site
-
East Orange, New Jersey, United States
- 502.373.0202 Boehringer Ingelheim Investigational Site
-
Newark, New Jersey, United States
- 502.373.0191 Boehringer Ingelheim Investigational Site
-
Westwood, New Jersey, United States
- 502.373.0271 Boehringer Ingelheim Investigational Site
-
-
New York
-
Bronx, New York, United States
- 502.373.0150 Boehringer Ingelheim Investigational Site
-
Brooklyn, New York, United States
- 502.373.0213 Boehringer Ingelheim Investigational Site
-
Buffalo, New York, United States
- 502.373.0230 Boehringer Ingelheim Investigational Site
-
Kingston, New York, United States
- 502.373.0288 Boehringer Ingelheim Investigational Site
-
New York, New York, United States
- 502.373.0238 Boehringer Ingelheim Investigational Site
-
New York, New York, United States
- 502.373.0252 Boehringer Ingelheim Investigational Site
-
New York, New York, United States
- 502.373.0286 Boehringer Ingelheim Investigational Site
-
Northport, New York, United States
- 502.373.0166 Boehringer Ingelheim Investigational Site
-
Rochester, New York, United States
- 502.373.0156 Boehringer Ingelheim Investigational Site
-
Rochester, New York, United States
- 502.373.0264 Boehringer Ingelheim Investigational Site
-
Scarsdale, New York, United States
- 502.373.0227 Boehringer Ingelheim Investigational Site
-
Westfield, New York, United States
- 502.373.0163 Boehringer Ingelheim Investigational Site
-
Williamsville, New York, United States
- 502.373.0241 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Durham, North Carolina, United States
- 502.373.0273 Boehringer Ingelheim Investigational Site
-
Winston Salem, North Carolina, United States
- 502.373.0261 Boehringer Ingelheim Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, United States
- 502.373.0222 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- 502.373.0155 Boehringer Ingelheim Investigational Site
-
Cleveland, Ohio, United States
- 502.373.0164 Boehringer Ingelheim Investigational Site
-
Dayton, Ohio, United States
- 502.373.0168 Boehringer Ingelheim Investigational Site
-
Mansfield, Ohio, United States
- 502.373.0159 Boehringer Ingelheim Investigational Site
-
Oklahoma City, Ohio, United States
- 502.373.0178 Boehringer Ingelheim Investigational Site
-
-
Oklahoma
-
Guthrie, Oklahoma, United States
- 502.373.0259 Boehringer Ingelheim Investigational Site
-
Oklahoma City, Oklahoma, United States
- 502.373.0154 Boehringer Ingelheim Investigational Site
-
Tulsa, Oklahoma, United States
- 502.373.0152 Boehringer Ingelheim Investigational Site
-
-
Oregon
-
Portland, Oregon, United States
- 502.373.0243 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, United States
- 502.373.0265 Boehringer Ingelheim Investigational Site
-
Philadelphia, Pennsylvania, United States
- 502.373.0153 Boehringer Ingelheim Investigational Site
-
Sellersville, Pennsylvania, United States
- 502.373.0274 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States
- 502.373.0184 Boehringer Ingelheim Investigational Site
-
Columbia, South Carolina, United States
- 502.373.0248 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Dallas, Texas, United States
- 502.373.0172 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, United States
- 502.373.0187 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, United States
- 502.373.0219 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, United States
- 502.373.0275 Boehringer Ingelheim Investigational Site
-
Fort Worth, Texas, United States
- 502.373.0221 Boehringer Ingelheim Investigational Site
-
Houston, Texas, United States
- 502.373.0206 Boehringer Ingelheim Investigational Site
-
Houston, Texas, United States
- 502.373.0234 Boehringer Ingelheim Investigational Site
-
Houston, Texas, United States
- 502.373.0280 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Burke, Virginia, United States
- 502.373.0249 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Seattle, Washington, United States
- 502.373.0281 Boehringer Ingelheim Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
- 502.373.0212 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.
Other High Risk:
- Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
- Previous stroke
- Transient ischemic Attack > 7 days and < 1 year prior to informed consent
- Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.
No definite and specific indication or contraindication for any of the study treatments. Written informed consent.
Exclusion Criteria:
A. Medication use:
- Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
- Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.
NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.
B. Cardiovascular disease:
- Symptomatic congestive heart failure.
- Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
- Constrictive pericarditis.
- Complex congenital heart disease.
- Syncopal episodes of unknown etiology < 3 months before informed consent.
- Planned cardiac surgery or angioplasty within three months.
- Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) > 160/100).
- Heart transplant recipient.
- Strokes due to subarachnoid hemorrhage
C. Other conditions:
Significant renal disease defined as:
- Renal artery stenosis;
- Creatinine clearance < 0.6 ml/min or serum creatinine > 265 umol/L (> 3.0 mg/dL);
- Hyperkalemia: potassium > 5.5 mmol/L.
- Proteinuria* (for TRANSCEND only).
- Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) > than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin > 20 umol/L, biliary obstructive disorders.
- Uncorrected volume depletion or sodium depletion.
- Primary aldosteronism.
- Hereditary fructose intolerance.
- Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.
- Patient is simultaneously taking another experimental drug.
- Patient with significant disability that precludes regular attendance at clinic for follow-up.
- Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.
- Unable or unwilling to provide written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Interventional Model: PARALLEL
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
|
56 months
|
|
ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients
Time Frame: 56 months
|
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline. These renal outcomes were not adjudicated (apart from death). |
56 months
|
|
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
|
56 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to first event analysis of the following defined endpoints, non-fatal myocardial infarction or non-fatal stroke
|
56 months
|
|
ONTARGET. Cardiovascular Death
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to the first event analysis of the endpoint cardiovascular death.
|
56 months
|
|
ONTARGET. Non-fatal Myocardial Infarction
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to the first event analysis of the endpoint non-fatal myocardial infarction.
|
56 months
|
|
ONTARGET. Non-fatal Stroke
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to first event analysis of the endpoint non-fatal stroke.
|
56 months
|
|
ONTARGET. Hospitalization for Congestive Heart Failure
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to the first event analysis of the endpoint hospitalization for congestive heart failure.
|
56 months
|
|
ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients
Time Frame: 56 months
|
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
|
56 months
|
|
ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients
Time Frame: 56 months
|
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73
m².
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
|
56 months
|
|
ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients
Time Frame: 56 months
|
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
|
56 months
|
|
ONTARGET. Doubling of Serum Creatinine
Time Frame: 56 months
|
ONTARGET.
Nephropathy subcategory: doubling of serum creatinine
|
56 months
|
|
ONTARGET. Progression to ESRD
Time Frame: 56 months
|
ONTARGET.
Nephropathy subcategory: Progression to ESRD.
Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73
m².
|
56 months
|
|
ONTARGET. New Microalbuminuria
Time Frame: 56 months
|
ONTARGET.
Nephropathy subcategory: New microalbuminuria.
New microalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥30 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <30 mg/g Crea at baseline.
|
56 months
|
|
ONTARGET. New Macroalbuminuria
Time Frame: 56 months
|
ONTARGET.
Nephropathy subcategory: New macroalbuminuria.
New macroalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥300 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <300 mg/g Crea at baseline.
|
56 months
|
|
ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria
Time Frame: 56 months
|
ONTARGET.
Nephropathy subcategory: Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria
|
56 months
|
|
ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
Time Frame: 56 months
|
ONTARGET.
Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria.
Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.
|
56 months
|
|
ONTARGET. Newly Diagnosed Congestive Heart Failure
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to the first event analysis of the endpoint Newly diagnosed Congestive Heart failure.
|
56 months
|
|
ONTARGET. Cardiovascular Revascularization Procedure
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
|
56 months
|
|
ONTARGET. Newly Diagnosed Diabetes
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to the first event analysis of the endpoint Newly diagnosed Diabetes.
Only calculated for those patients without diabetes at baseline.
|
56 months
|
|
ONTARGET. Cognitive Decline
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to first event analysis of the endpoint cognitive decline i.e.
Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial.
A decrease in MMSE from baseline represents a cognitive decline.
This outcome measure is only available for those patients who had MMSE at baseline.
|
56 months
|
|
ONTARGET. New Onset of Atrial Fibrillation
Time Frame: 56 months
|
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Time to first event analysis of endpoint new onset of atrial fibrillation.
|
56 months
|
|
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
|
56 months
|
|
TRANSCEND. Cardiovascular Death
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Time to the first event analysis of the endpoint cardiovascular death.
|
56 months
|
|
TRANSCEND. Non-fatal Myocardial Infarction
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Time to the first event analysis of the endpoint non-fatal myocardial infarction.
|
56 months
|
|
TRANSCEND. Non-fatal Stroke
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
|
56 months
|
|
TRANSCEND. Hospitalization for Congestive Heart Failure
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
|
56 months
|
|
TRANSCEND. Doubling of Serum Creatinine
Time Frame: 56 months
|
TRANSCEND.
Nephropathy subcategory: doubling of serum creatinine
|
56 months
|
|
TRANSCEND. Progression to ESRD
Time Frame: 56 months
|
TRANSCEND.
Nephropathy subcategory: Progression to ESRD.
Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73m²
|
56 months
|
|
TRANSCEND. New Microalbuminuria
Time Frame: 56 months
|
TRANSCEND.
Nephropathy subcategory: New microalbuminuria.
New microalbuminuria is defined as UACR ≥30 mg/g creatinine [Crea] in patients with a UACR <30 mg/g Crea at baseline
|
56 months
|
|
TRANSCEND. New Macroalbuminuria
Time Frame: 56 months
|
TRANSCEND.
Nephropathy subcategory: New macroalbuminuria.
New macroalbuminuria is defined as UACR ≥300 mg/g creatinine [Crea] in patients with a UACR <300 mg/g Crea at baseline
|
56 months
|
|
TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria
Time Frame: 56 months
|
TRANSCEND.
Nephropathy subcategory: Combined endpoint of doubling serum creatinine, progression to ESRD, new microalbuminuria or new macroalbuminuria
|
56 months
|
|
TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
Time Frame: 56 months
|
TRANSCEND.
Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria.
Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.
|
56 months
|
|
TRANSCEND. New Onset of Atrial Fibrillation
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
|
56 months
|
|
TRANSCEND. Cognitive Decline
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Time to first event analysis of the endpoint cognitive decline i.e.
Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial.
A decrease in MMSE from baseline represents a cognitive decline.
This outcome measure is only available for those patients who had MMSE at baseline.
|
56 months
|
|
TRANSCEND. Newly Diagnosed Diabetes
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Time to the first event analysis of the endpoint Newly diagnosed Diabetes.
Only calculated for those patients without diabetes at baseline.
|
56 months
|
|
TRANSCEND. Cardiovascular Revascularization Procedure
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
|
56 months
|
|
TRANSCEND. Newly Diagnosed Congestive Heart Failure
Time Frame: 56 months
|
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
|
56 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bohm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Laufs U, Williams B, Yusuf S, Mann JFE. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w.
- Bohm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE, Mahfoud F. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021 Aug 1;39(8):1602-1610. doi: 10.1097/HJH.0000000000002822.
- Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, Mancia G, Redon J, Schmieder RE, Sliwa K, Lehrke M, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697.
- Mancia G, Schumacher H, Bohm M, Mann JFE, Redon J, Facchetti R, Schmieder RE, Lonn EM, Teo KK, Yusuf S. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020 Oct;38(10):2050-2058. doi: 10.1097/HJH.0000000000002567.
- Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, Khatib R, Altuntas Y, Liu X, Iqbal R, Rosengren A, Yusuf R, Smuts M, Yusufali A, Li N, Diaz R, Yusoff K, Kaur M, Soman B, Ismail N, Gupta R, Dans A, Sheridan P, Teo K, Anand SS, Yusuf S. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. Am J Clin Nutr. 2020 Apr 1;111(4):795-803. doi: 10.1093/ajcn/nqz348.
- Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149.
- Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020 Jan 7;41(2):231-238. doi: 10.1093/eurheartj/ehy808.
- Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
- Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R. Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv76-85. doi: 10.1093/ndt/gfv086.
- Bohm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.
- Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.
- Lonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, Bohm M. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014 Feb;103(2):149-59. doi: 10.1007/s00392-013-0644-4. Epub 2013 Dec 20.
- Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.
- Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med. 2013 Oct 14;173(18):1682-92. doi: 10.1001/jamainternmed.2013.9051.
- Bohm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24.
- Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.
- Barzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, Yusuf S, Teo KK; OnTARGET/TRANSCEND Investigators. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clin J Am Soc Nephrol. 2013 Feb;8(2):233-40. doi: 10.2215/CJN.06640712. Epub 2012 Nov 26.
- Kappert K, Bohm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24.
- Neumann I, Grassi B. [Critically appraised article]. Rev Med Chil. 2012 Jan;140(1):117-20. Epub 2012 Apr 12. Spanish.
- Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.
- Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.
- Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26.
- Barzilay JI, Gao P, Ryden L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K; TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011 Sep;34(9):1902-7. doi: 10.2337/dc11-0545. Epub 2011 Jul 25.
- Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28.
- Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, Probstfield J, Dagenais GR, Teo K, Yusuf S; ONTARGET and TRANSCEND Investigators. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med. 2011 Jan 24;171(2):142-50. doi: 10.1001/archinternmed.2010.502.
- Dans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, Chaithiraphan S, Zhu J, Lisheng L, Yusuf S; Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One. 2010 Dec 21;5(12):e13694. doi: 10.1371/journal.pone.0013694.
- Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S; ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 Jan;10(1):43-53. doi: 10.1016/S1474-4422(10)70250-7. Epub 2010 Oct 25.
- Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.
- Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21.
- Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370.
- Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Ryden L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18.
- Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Erratum In: Lancet. 2008 Oct 18;372(9647):1384.
- Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.
- ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.
- Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007 Mar 20;115(11):1371-5. doi: 10.1161/CIRCULATIONAHA.106.661405. Epub 2007 Mar 5.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2001
Primary Completion (ACTUAL)
June 1, 2008
Study Registration Dates
First Submitted
September 9, 2005
First Submitted That Met QC Criteria
September 9, 2005
First Posted (ESTIMATE)
September 12, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
May 20, 2014
Last Update Submitted That Met QC Criteria
May 13, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 502.373
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Telmisartan
-
Emory UniversityNational Institute on Aging (NIA)Completed
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedDiabetic NephropathiesJapan
-
Boehringer IngelheimCompleted
-
Laboratorio Elea Phoenix S.A.Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBACompleted